Tau and amyloid beta (Aβ) are the prime suspects for driving pathology in Alzheimer's
disease (AD) and, as such, have become the focus of therapeutic development. Recent …

Alzheimer disease (AD) represents an oncoming epidemic that without an effective
treatment promises to exact extraordinary human and financial burdens. Studies of …

Alzheimer's disease (AD) is the most common form of dementia and may contribute to 60–
70% of cases. Worldwide, around 50 million people suffer from dementia and the prediction …

The number of biological therapeutic agents in the clinic and development pipeline has
increased dramatically over the last decade and the number will undoubtedly continue to …

A hallmark of Alzheimer's disease (AD) is the aggregation of β-amyloid peptides (Aβ) into
amyloid plaques in patient brain. Cleavage of amyloid precursor protein (APP) by the …

This review is concerned with the role of fibrillization of the amyloid β (Aβ)-peptide in
Alzheimer's disease (AD). The perspective is that of a physical chemist, and one aim is to …

Alzheimer's disease (AD) is the most common type of senile dementia, characterized by
neurofibrillary tangle and amyloid plaque in brain pathology. Major efforts in AD drug were …

Alzheimer's disease (AD) 1− 3 is the most common form of dementia (estimated∼ 50− 60%
of all cases), associated with loss of memory (in particular episodic memory), cognitive …

Aluminum (Al) is a ubiquitous substance encountered both naturally (as the third most
abundant element) and intentionally (used in water, foods, pharmaceuticals, and vaccines); …

The amyloid β peptide (Aβ) is a critical initiator that triggers the progression of Alzheimer's
Disease (AD) via accumulation and aggregation, of which the process may be caused by Aβ …